Emmaus Life Sciences Board Changes and Officer Compensation
Ticker: EMMA · Form: 8-K · Filed: Nov 6, 2024 · CIK: 822370
| Field | Detail |
|---|---|
| Company | Emmaus Life Sciences, INC. (EMMA) |
| Form Type | 8-K |
| Filed Date | Nov 6, 2024 |
| Risk Level | medium |
| Pages | 1 |
| Reading Time | 2 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: board-change, executive-compensation, governance
TL;DR
Emmaus Life Sciences board shakeup: Dr. Kim joins, Mr. Smith exits. Officer pay details also out.
AI Summary
Emmaus Life Sciences, Inc. announced on November 4, 2024, a change in its board of directors. Specifically, Dr. Y. K. Kim has been appointed as a new director, and Mr. David L. L. Smith has resigned from the board. The company also disclosed compensatory arrangements for its officers.
Why It Matters
Changes in board composition and executive compensation can signal shifts in company strategy or governance, potentially impacting investor confidence and future performance.
Risk Assessment
Risk Level: medium — Board changes and executive compensation disclosures can introduce uncertainty about future strategic direction and management stability.
Key Players & Entities
- Emmaus Life Sciences, Inc. (company) — Registrant
- Dr. Y. K. Kim (person) — Newly appointed director
- Mr. David L. L. Smith (person) — Resigned director
- November 4, 2024 (date) — Date of earliest event reported
FAQ
Who has been appointed as a new director to the Emmaus Life Sciences board?
Dr. Y. K. Kim has been appointed as a new director.
Who has resigned from the Emmaus Life Sciences board of directors?
Mr. David L. L. Smith has resigned from the board.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is November 4, 2024.
What other information is disclosed in this filing besides director changes?
The filing also discloses compensatory arrangements of certain officers.
In which state is Emmaus Life Sciences, Inc. incorporated?
Emmaus Life Sciences, Inc. is incorporated in Delaware.
Filing Stats: 432 words · 2 min read · ~1 pages · Grade level 10.6 · Accepted 2024-11-06 16:00:26
Filing Documents
- ea0220098-8k_emmaus.htm (8-K) — 26KB
- 0001213900-24-094976.txt ( ) — 190KB
- emma-20241104_lab.xml (EX-101.LAB) — 33KB
- emma-20241104_pre.xml (EX-101.PRE) — 22KB
- emma-20241104.xsd (EX-101.SCH) — 3KB
- ea0220098-8k_emmaus_htm.xml (XML) — 3KB
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 104 Cover Page Interactive Data File (embedded within the inline XBRL Document) 1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 6, 2024 EMMAUS LIFE SCIENCES, INC. By: /s/ YASUSHI NAGASAKI Name: Yasushi Nagasaki Title: Chief Financial Officer 2